Full Press Release Details
Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy.
RARE
Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy
Key Takeaway: Ultragenyx Announces Completion of Phase 2 Study Enrollment for UX001 in Hereditary Inclusion Body Myopathy